Percutaneous Tibial Nerve Stimulation in the Treatment of Fecal Incontinence
Primary Purpose
Fecal Incontinence
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Urgent PC neuromodulation system
Urgent PC neuromodulation system
Sponsored by
About this trial
This is an interventional treatment trial for Fecal Incontinence focused on measuring Fecal incontinence
Eligibility Criteria
Inclusion Criteria:
- Written informed consent
- Must be at least 18 years of age
- Fecal incontinence with solid or liquid stool causing disruption of the subject's lifestyle
- Psychological stability as determined by treating physician
- Willingness to commit to a rigid follow-up schedule and comply with the investigational plan
- Failed conservative therapy (i.e. dietary and behavioural modification, biofeedback techniques and exercises for pelvic floor muscle retraining)
- During treatment the patient exhibits an adequate motor and/or sensory response (flexion of toe and/or twinkling sensation)
- Is able to read and write
Exclusion Criteria:
- Major internal and/or external sphincter defect (defined as >33% of the anal circumference)
- Fecal impaction
- Pacemaker, implanted defibrillator
- Pregnancy or intention to become pregnant
- Neurogenic or congenital disorders resulting in FI
- Inability to travel to the clinic twice a week
Sites / Locations
- CCDE - IMAD - Hôtel-Dieu
- Università degli Studi di Roma "La Sapienza"
- Maastricht university medical center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
Treatment group
sham group
Arm Description
Treatment group
Sham group
Outcomes
Primary Outcome Measures
The percentage of patients experiencing a ≥ 50% decrease in incontinence episodes from baseline after 9 weeks of treatment and at six and twelve months follow-up.
Secondary Outcome Measures
Mean change in the Cleveland Clinic Florida Fecal Incontinence Score (CCF-FI Score) at 6 weeks and 9 weeks of treatment and at six and twelve months follow-up.
Mean change in Quality of Life scores in validated QoL questionnaires (SF-36, Digestive Health Status Instrument (DHSI), and Fecal Incontinence Quality of life) at 6 weeks and 9 weeks of treatment and at six and twelve months follow-up.
Subject's and Physician's Global Impression at 6 weeks and 9 weeks of treatment and at six and twelve months follow-up.
Full Information
NCT ID
NCT00974909
First Posted
September 8, 2009
Last Updated
August 25, 2015
Sponsor
Maastricht University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT00974909
Brief Title
Percutaneous Tibial Nerve Stimulation in the Treatment of Fecal Incontinence
Official Title
Percutaneous Tibial Nerve Stimulation in the Treatment of Fecal Incontinence: a Multi-center, Randomized, Placebo Controlled Study
Study Type
Interventional
2. Study Status
Record Verification Date
September 2010
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
October 2011 (Actual)
Study Completion Date
August 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maastricht University Medical Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Background of the study:
Fecal incontinence is a complex problem. The social consequences of this problem result in a lower quality of life. The exact prevalence of FI is unknown, literature reports vary from 13-19%. There are variable treatment options depending on the patient and the etiology of the FI. Dietary manipulation, pharmacological intervention, pelvic floor physiotherapy, as well as surgical interventions are currently used to treat FI.
A promising current treatment is Percutaneous Tibial Nerve Stimulation (PTNS). The nerves in the spine that control bowel function also have branches which go to the ankle. Stimulating these nerves in the ankle has shown to be an effective treatment for FI in the short-term. The treatment has been shown to be safe and well tolerated by subjects with almost no morbidity in prior urology trials.
Objective of the study:
The objective of this study is to show that the results of PTNS are based on the treatment of electrical stimulation and not on a placebo effect with a sham treatment.
Study design:
This study is a multicenter, single-blinded, randomized, placebo-controlled trial.
Primary study parameters/outcome of the study:
The percentage of patients experiencing a ≥ 50% decrease in incontinence episodes from baseline after 9 weeks of treatment.
Secondary study parameters/outcome of the study (if applicable):
Mean change in the Cleveland Clinic Florida Fecal Incontinence Score (CCF-FI Score)
Mean change in Quality of Life scores in validated QoL questionnaires (SF-36, Digestive Health Status Instrument (DHSI), and Fecal Incontinence Quality of life)
Subject's and Physician's Global Impression
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fecal Incontinence
Keywords
Fecal incontinence
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
59 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Treatment group
Arm Type
Active Comparator
Arm Description
Treatment group
Arm Title
sham group
Arm Type
Sham Comparator
Arm Description
Sham group
Intervention Type
Device
Intervention Name(s)
Urgent PC neuromodulation system
Intervention Description
Urgent PC neuromodulation system
Intervention Type
Device
Intervention Name(s)
Urgent PC neuromodulation system
Intervention Description
Urgent PC neuromodulation system (sham)
Primary Outcome Measure Information:
Title
The percentage of patients experiencing a ≥ 50% decrease in incontinence episodes from baseline after 9 weeks of treatment and at six and twelve months follow-up.
Time Frame
9 weeks
Secondary Outcome Measure Information:
Title
Mean change in the Cleveland Clinic Florida Fecal Incontinence Score (CCF-FI Score) at 6 weeks and 9 weeks of treatment and at six and twelve months follow-up.
Time Frame
one year
Title
Mean change in Quality of Life scores in validated QoL questionnaires (SF-36, Digestive Health Status Instrument (DHSI), and Fecal Incontinence Quality of life) at 6 weeks and 9 weeks of treatment and at six and twelve months follow-up.
Time Frame
one year
Title
Subject's and Physician's Global Impression at 6 weeks and 9 weeks of treatment and at six and twelve months follow-up.
Time Frame
one year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Written informed consent
Must be at least 18 years of age
Fecal incontinence with solid or liquid stool causing disruption of the subject's lifestyle
Psychological stability as determined by treating physician
Willingness to commit to a rigid follow-up schedule and comply with the investigational plan
Failed conservative therapy (i.e. dietary and behavioural modification, biofeedback techniques and exercises for pelvic floor muscle retraining)
During treatment the patient exhibits an adequate motor and/or sensory response (flexion of toe and/or twinkling sensation)
Is able to read and write
Exclusion Criteria:
Major internal and/or external sphincter defect (defined as >33% of the anal circumference)
Fecal impaction
Pacemaker, implanted defibrillator
Pregnancy or intention to become pregnant
Neurogenic or congenital disorders resulting in FI
Inability to travel to the clinic twice a week
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cornelius Baeten, prof phd md
Organizational Affiliation
Maastricht University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
CCDE - IMAD - Hôtel-Dieu
City
Nantes
ZIP/Postal Code
F - 44093
Country
France
Facility Name
Università degli Studi di Roma "La Sapienza"
City
Roma
ZIP/Postal Code
00185
Country
Italy
Facility Name
Maastricht university medical center
City
Maastricht
State/Province
Limburg
ZIP/Postal Code
6229 HX
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
28703936
Citation
van der Wilt AA, Giuliani G, Kubis C, van Wunnik BPW, Ferreira I, Breukink SO, Lehur PA, La Torre F, Baeten CGMI. Randomized clinical trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in patients with faecal incontinence. Br J Surg. 2017 Aug;104(9):1167-1176. doi: 10.1002/bjs.10590.
Results Reference
derived
Learn more about this trial
Percutaneous Tibial Nerve Stimulation in the Treatment of Fecal Incontinence
We'll reach out to this number within 24 hrs